NEW YORK, March 28, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE:
MRK), Pfizer Inc. (NYSE: PFE), Amgen Inc. (NASDAQ: AMGN), and
Allergan Inc. (NYSE: AGN). Private wealth members receive these
notes ahead of publication. To reserve complementary membership,
limited openings are available at:
http://www.AnalystsReview.com/register
--
Johnson & Johnson Analyst Notes
On March 24, 2014, Johnson &
Johnson reported that on March 21,
2014, Janssen R&D Ireland (Janssen) announced the
receipt of a positive opinion from the Committee for Medicinal
Products for Human Use (CHMP), with recommendation for Marketing
Authorization in the European Union for the use of simeprevir in
combination with other medicinal products for the treatment of
chronic hepatitis C (CHC) in adult patients. According to Janssen,
the CHMP opinion was based on positive consistent results from
three pivotal Phase 3 studies in patients with genotype 1 HCV:
QUEST-1 and QUEST-2 in treatment-naïve patients and PROMISE in
patients who have relapsed after prior interferon-based treatment.
Additionally, Janssen stated that a final decision on simeprevir by
the European Commission is anticipated during Q2 2014. Brian Woodfall, Head of Development & Global
Medical Affairs, Infectious Diseases/Vaccines, Janssen, stated,
"The CHMP positive opinion for simeprevir brings us another step
closer to delivering an innovative therapy for patients suffering
from this devastating disease. Simeprevir offers a potentially new
treatment option and therefore renewed hope to people living with
HCV." The full analyst notes on Johnson & Johnson are available
to download free of charge at:
http://www.AnalystsReview.com/03282014/JNJ/report.pdf
--
Merck & Co. Inc. Analyst Notes
On March 24, 2014, Merck & Co.
Inc. (Merck) announced that the new Phase 2 data for its two
investigational hepatitis C virus (HCV) treatments - MK-5172 and
MK-8742 are scheduled to be presented at the 49th Annual
Meeting of the European Association for the Study of the Liver
(EASL) also known as The International Liver Congress™ 2014 on
April 9, 2014, to April 13, 2014, in London, UK. Dr. Eliav
Barr, Vice President, Infectious Disease, Merck Research
Laboratories, stated, "These additional clinical data for MK-5172
and MK-8742 build upon the clinical evidence collected to date
across a broad spectrum of patients with chronic HCV. Based on
these data, we are pursuing a Phase 3 clinical program for these
potentially important investigational medicines." The full analyst
notes on Merck & Co. Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03282014/MRK/report.pdf
--
Pfizer Inc. Analyst Notes
On March 25, 2014, Pfizer Inc.
(Pfizer) announced that the PROFILE 1014, a Phase 3 study of
anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib),
met its primary objective of significantly prolonging
progression-free survival in previously untreated patients with
ALK-positive advanced non-squamous non-small cell lung cancer
(NSCLC) against standard platinum-based chemotherapy regimens.
According to the Company, PROFILE 1014 is the second positive
global Phase 3 study that evaluated XALKORI against chemotherapy.
Additionally, the Company stated that no unexpected safety issues
were identified in the PROFILE 1014 study. Dr. Mace Rothenberg,
Senior Vice President of Clinical Development and Medical Affairs
and Chief Medical Officer of Pfizer Oncology, stated, "The results
of the PROFILE 1014 study are important in that they demonstrate,
for the first time, that XALKORI is superior to standard
chemotherapy doublet regimens in prolonging survival without
progression as first-line treatment for patients with ALK-positive
advanced NSCLC. These findings build upon the data from the PROFILE
1007 randomized Phase 3 study in previously treated patients and
collectively establish XALKORI as a standard of care in both the
first and second-line setting for patients with ALK-positive
advanced NSCLC." The full analyst notes on Pfizer Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03282014/PFE/report.pdf
--
Amgen Inc. Analyst Notes
On March 24, 2014, Amgen Inc.
(Amgen) announced that it will present the pivotal Phase 3 data
from five clinical studies evaluating evolocumab (AMG 145).
According to the Company, the results from the five Phase 3 studies
with evolocumab are scheduled to be presented in three Featured
Clinical Research and two Late-Breaking Clinical Trial sessions
from March 29, 2014 to March 31, 2014, at the American College of
Cardiology's 63rd Annual Scientific Session (ACC. 14) in
Washington, DC. Sean E. Harper, M.D. Executive Vice President of
Research and Development at Amgen, stated, "We are eager to share
the detailed findings from our Phase 3 cholesterol-lowering studies
of evolocumab at ACC. The robust data from these studies in more
than 4,000 patients form the basis of our global filing plan and we
look forward to potentially providing a new treatment option to
improve the lives of patients with high cholesterol, who have
increased LDL-C levels despite existing therapies." The full
analyst notes on Amgen Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03282014/AMGN/report.pdf
--
Allergan Inc. Analyst Notes
On March 25, 2014, Allergan Inc.'s
(Allergan) stock went up by 0.15%, closing the day's session at
$124.57. In the past three months,
Allergan shares went up by 14.68%, compared to the Dow Jones
Industrial Average Index which went up by 0.06% during the same
period. The full analyst notes on Allergan Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03282014/AGN/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review